INmune Bio (INMB) vs Metagenomi Therapeutics (MGX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
INmune Bio (INMB) has outperformed Metagenomi Therapeutics (MGX) over the past year, losing 45.2% versus a loss of 62.6%. INmune Bio is the larger company by market cap ($25.6 million vs $21.4 million), about 1.2 times the size. Metagenomi Therapeutics converts more of its revenue into profit, with a net margin of -348.5% versus -91866.0%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | INMB | MGX |
|---|---|---|
| Share price | $0.827 | $0.565 |
| Market cap | $25.60M | $21.36M |
| 1-day change | -7.50% | -7.95% |
| YTD return | -46.99% | -65.12% |
| 1-year return | -45.23% | -62.58% |
| 5-year return | -93.80% | — |
| EPS (TTM) | $-0.60 | $-2.50 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $50.00K | $25.21M |
| Revenue growth (YoY) | +257.14% | -51.79% |
| Net income (latest FY) | $-45.93M | $-87.87M |
| Operating margin | -94766.00% | -380.85% |
| Net margin | -91866.00% | -348.54% |
| 52-week high | $2.60 | $1.87 |
| 52-week low | $0.8189 | $0.562 |
| Distance from 52-week high | -68.19% | -69.79% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +746.43% | +1138.94% |
| Average volume | 338.47K | 163.21K |
| Shares outstanding | 30.96M | 37.81M |
| Employees | 21 | 113 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- INMB has outperformed MGX by 17.4 percentage points over the past year.
- Metagenomi Therapeutics is more profitable, keeping -348.5 cents of every revenue dollar as net income versus -91866.0 cents for INmune Bio.
- INmune Bio grew revenue faster in its latest fiscal year (+257.14% vs -51.79%).
About INmune Bio
INMB stock →INmune Bio Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 21 employees
About Metagenomi Therapeutics
MGX stock →Metagenomi Therapeutics, Inc. an in vivo genome editing company, develops curative genetic medicines in the United States.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 113 employees
INMB vs MGX FAQ
Which is bigger, INmune Bio or Metagenomi Therapeutics?
INmune Bio (INMB) is larger, with a market capitalization of $25.60M compared with $21.36M for Metagenomi Therapeutics (MGX).
Which stock has performed better over the past year, INMB or MGX?
INMB returned -45.23% over the past 12 months, compared with -62.58% for MGX (price return, excluding dividends). Past performance does not predict future results.
Are INmune Bio and Metagenomi Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.